Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761784 · ClinicalTrials.gov registry record · Phase 3
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
NCT03761784 is a Phase 3 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 424 participants.
The verdict
NCT03761784, a Phase 3 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
Study Summary
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Interventions
- DRUG S6G5T-3
- DRUG S6G5T-8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761784
The ClinicalTrials.gov registry entry for NCT03761784 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S6G5T-3 is the first listed.
NCT03761784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03761784 about?
NCT03761784 is a clinical study titled "A Study of S6G5T-3 in the Treatment of Acne Vulgaris". To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
What is the current status of trial NCT03761784?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2018-12-21. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03761784?
The interventions under investigation include: S6G5T-3 (DRUG), S6G5T-8 (DRUG).
Who is sponsoring clinical trial NCT03761784?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.